8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Boston Scientific reports 7.5% second-quarter sales growth and raises full-year EPS outlook
Filed with the SEC on · Summarized by InvestorsBot
Boston Scientific reported second-quarter 2026 net sales of $5.442 billion, up 7.5% year over year, with GAAP diluted EPS of $0.61 and adjusted EPS of $0.86, above its $0.82-$0.84 guidance range. The company completed a $2 billion accelerated share repurchase, invested $1.5 billion in MiRus for an approximately 34% stake and an option to acquire its TAVR business, and now expects full-year 2026 adjusted EPS of $3.28-$3.32 and organic sales growth of 5%-6%.